<DOC>
	<DOCNO>NCT00841568</DOCNO>
	<brief_summary>Investigation long-term safety efficacy OPC-41061 repeat oral administration dose 15 mg twice daily patient ADPKD complete precede dose-finding study ( 156-04-001 ) .</brief_summary>
	<brief_title>A Long-term Administration Study OPC-41061 Patients With Autosomal Dominant Polycystic Kidney Disease ( ADPKD ) Extension Study 156-04-001</brief_title>
	<detailed_description>Investigation long-term safety efficacy OPC-41061 repeat oral administration dose 15 mg twice daily patient ADPKD complete precede dose-finding study ( 156-04-001 ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients complete 5day repeated administration followup observation preceding study ( 15604001 ) Patients safety repeat administration confirm base investigator 's report precede study ( 15604001 ) Patients serum creatinine concentration 2.5 mg/dL high screen examination Patients follow complication Uncontrolled hypertension Serious cardiovascular disease ( eg . heart failure ) hepatic disease ( eg . cirrhosis ) '' Patients follow complication history thereof Clinically significant drug allergy ( anaphylaxis ) hypersensitivity ( especially , hypersensitivity benzazepine derivative suspect hypersensitivity thereto ) Inability personally give consent due mental disease `` Patients SBP ( sit position ) &lt; 90 mm Hg ( screen examination ) Patients history massive bleeding bleeding tendency Patients history drug alcohol abuse within 6 month prior screen examination Pregnant woman , lactate woman , woman may become plan become pregnant Patients receive investigational drug OPC41061 within 30 day prior commencement administration OPC41061 Any patient , opinion principle investigator attend investigator , participate study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>Tolvaptan</keyword>
</DOC>